Following its presentation at the ATS 2025 International Conference, the poster will also be made available on the "Posters & Publications" section of the Gossamer ...

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target ...

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off ...

~ Presentation to highlight the potential of Gennao’s proprietary, non-viral gene monoclonal antibody (GMAB) platform technology to systemically target medulloblastoma in vivo ~ ~ The GMAB platform ...

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced the company will present one poster concerning Phase 1 clinical ...

Sonnet BioTherapeutics Holdings, Inc. announced that its abstract has been accepted for a poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference, scheduled for ...

A few years ago, presenting a poster at a scientific conference inevitably meant battling with thumbtacks, rubber bands, and an unwieldly sail of paper with little power to inspire. Now researchers ...

LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT”) cell ...